Biomedical Research in Developing Countries - UNICRI

More documents

Recommendations

Info

MOROCCO National specific legislation on ethics in biomedical research Guidelines and/or SOPs concerning ethics in research National/Institutional Bioethics Committees that review ethics of biomedical research with human participants NO N/A YES Sources: 1) A+Science, A+ Science initiates Clinical trial symposium held in Morocco, 2008 (Accessed on 9 July 2008 at http://www.aplusscience.com/index.cfm/en/news/latest_news2/?archive&prid=32) 2) Barnes K., Morocco vying for clinical trial attention, Outsourcing pharma.com, 2006 (Accessed on 9 July 2008 at http://www.outsourcingpharma.com/news/ng.asp?id=71392-ppd-morocco-clinical-trials) 3) Hassar M., Recherche en santé, Institut Pasteur du Maroc, Pharmacologie Clinique, 2005 (Accessed on 9 July 2008 at http://www.emro.who.int/morocco/docs/fr/RS.pdf) 4) Hassi H., Recherches cliniques, Le Maroc encore à la traîne, L’Economiste, 2008 (Accessed on 9 July 2008 at http://www.leconomiste.com/print_article.html?a=83390) 5) R.K., L’éthique de la recherche scientifique, Le Maroc n’est pas doté d’un arsenal juridique qui encadre cette activité, Lematin.ma, 2007 (Accessed on 5 Septembre 2008 at http://www.lematin.ma/Actualite/Journal/Article.asp?idr=116&id=76421) 6) Royaume du Maroc, Ministère de la Sante, Circuit du médicament au sein de L.N.C.M., (Date unknown), (Accessed on 5 Septembre 2008 at http://www.sante.gov.ma/Departements/DMP/lncm/circuitsmedic.htm ) 7) Royaume du Maroc, Ministère de la Santé, Division de la Direction du Médicament et de la Pharmacie, (Accessed on 5 Septembre 2008 at http://www.sante.gov.ma/Departements/DMP/lncm/lncmpresenta.htm ) 8) Tazi A., Les Comités d’Éthique au Maroc et dans la région: États des lieux et enjeux, 2005 (Accessed on 9 July 2008 at http://www.emro.who.int/morocco/docs/fr/EL.pdf) 9) UNESCO - United Nations Educational, Scientific and Cultural Organization, Global Ethics Observatory, (Accessed on 30 September 2008 at http://www.unesco.org/shs/ethics/geo/user/?action=select&lng=en&db=) 10) WHO/EMRO – World Health Organization Regional Office for the Eastern Mediterranean, Colloque National de Bioéthique, Atelier de Formation à l’éthique de la recherche, Recommendations, Faculté de Médecine et de Pharmacie de Fès, Fès 8-11 Juin 2005 (Accessed on 9 July 2008 at http://www.emro.who.int/morocco/docs/en/Recommandations.pdf) 182
11) WHO/EMRO - World Health Organization Regional Office for the Eastern Mediterranean, UNESCO - United Nations Educational, Scientific and Cultural Organization, First Regional Meeting of National Bioethics Committees, Cairo 5/7 May 2007 (Accessed on 30 September 2008 at http://unesdoc.unesco.org/images/0015/00152805e.pdf) 12) Zayyoun A., Maaroufi A., Khyati M., Rapport de recherche: Analyse du système de recherche en santé, Royaume du Maroc, Ministère de la Santé, DELM-Direction de l’Epidémiologie et de la Lutte contre les Maladies and WHO/EMRO - World Health Organisation Regional Office for the Eastern Mediterranean, 2003 (Accessed on 9 July 2008 at http://doc.abhatoo.net.ma/DOC/IMG/pdf/Raport_20RSS.pdf) 13) Ziraoui Y., Médecine. Le labyrinthe des tests cliniques,Tel Quel on-line, 2008, No. 302 (Accessed on 9 July 2008 at http://www.telquel-online.com/302/maroc2_302.shtml) 183
Page 1 and 2:
Agenzia Italiana del Farmaco GCP IN
Page 3 and 4:
Table of Contents Authorship and Ac
Page 5 and 6:
World Health Organization - WHO . .
Page 7:
Annexes - International Round Table
Page 10 and 11:
University of Oxford/Kemri and Well
Page 12 and 13:
- this chapter also contains 42 cou
Page 14 and 15:
UNICRI facilitates global partnersh
Page 17 and 18:
PRESENTATION In welcoming the publi
Page 19:
3) the existence of centres or rese
Page 22 and 23:
3) the possibility to utilize a lar
Page 24 and 25:
ethical and psychosocial problems i
Page 27 and 28:
CHAPTER I THE INTERNATIONAL GUIDANC
Page 29 and 30:
makers and the community in develop
Page 31 and 32:
therapeutic methods identified by t
Page 33 and 34:
to conduct large-scale trials for v
Page 35 and 36:
preparatory work on a declaration o
Page 37 and 38:
Consequently, these authorities rar
Page 39 and 40:
new scientific developments made ac
Page 41 and 42:
Additional Protocols are foreseen i
Page 43 and 44:
applied in the protection of partic
Page 45 and 46:
Guidelines for Good Clinical Practi
Page 47 and 48:
Ethical and Policy Issues in Intern
Page 49 and 50:
Drug Development Research in Resour
Page 51 and 52:
Educating Bioethics Committees Guid
Page 53 and 54:
processes and stifle competition, d
Page 55 and 56:
European Medical Writers Associatio
Page 57 and 58:
prescribed to more than two million
Page 59:
Transparency is important both in t
Page 62 and 63:
investments in research”. Current
Page 64 and 65:
identify their needs and to plan fo
Page 66 and 67:
societies. The Foundation also host
Page 68 and 69:
annual, interdisciplinary and inter
Page 70 and 71:
project in the respect of internati
Page 72 and 73:
also to assess the training needs o
Page 74 and 75:
Fogarty International Center for Ad
Page 76 and 77:
Global Forum on Bioethics in Resear
Page 78 and 79:
the trainees home countries. Based
Page 80 and 81:
consolidate it in the fields of edu
Page 82 and 83:
KHRC is part of the INDEPTH Network
Page 84 and 85:
Research Center on Health, Cultures
Page 86 and 87:
Science with Africa The Science wit
Page 88 and 89:
exchange in health research ethics
Page 90 and 91:
objectives of SIDCER are to foster
Page 92 and 93:
national institutions, Tuskegee Uni
Page 94 and 95:
The Office for Human Research Prote
Page 96 and 97:
esearch, neuro-ethics, good clinica
Page 98 and 99:
are TDR (UNICEF/UNDP/World Bank/WHO
Page 100 and 101:
committees or scientific advisory c
Page 102 and 103:
The objective of the course was to
Page 104 and 105:
104
Page 106 and 107:
as passive recipients or, worse, as
Page 108 and 109:
THE HEALTH CARE SCENARIO IN THE DEV
Page 110 and 111:
Unfortunately, the “10/90 gap”
Page 112 and 113:
about 2,075 molecules were in devel
Page 114 and 115:
PATENTING ISSUES AND ACCESS TO ESSE
Page 116 and 117:
only on innovative products. A pate
Page 118 and 119:
In Africa, especially in the Sub-Sa
Page 120 and 121:
States agreed to increase funding f
Page 122 and 123:
very critical and difficult to ensu
Page 124 and 125:
The Botswana study was terminated a
Page 126 and 127:
THE CAPACITY FOR EDUCATION AND RESE
Page 128 and 129:
THE AFRICAN DIASPORA The need for A
Page 130 and 131:
with South Africa and Egypt account
Page 132 and 133: Political and social instability, a
Page 134 and 135: 2) Promoting independence from poli
Page 136 and 137: 136
Page 138 and 139: health care become critical issues.
Page 140 and 141: not yet developed a uniform model f
Page 142 and 143: In order to calculate the percentag
Page 144 and 145: Finally, the analysis was performed
Page 146 and 147: there can be considerable differenc
Page 148 and 149: The diffusion of GCP Inspectorates
Page 150 and 151: Table 5 - List of not analyzed coun
Page 152 and 153: ANGOLA National specific legislatio
Page 154 and 155: BOTSWANA National specific legislat
Page 156 and 157: BURUNDI National specific legislati
Page 158 and 159: 10) République du Cameroun, Minist
Page 160 and 161: CHAD National specific legislation
Page 162 and 163: COTE D’IVOIRE National specific l
Page 164 and 165: EGYPT National specific legislation
Page 166 and 167: EQUATORIAL GUINEA National specific
Page 168 and 169: 8) Mengistie G., Health research et
Page 170 and 171: GAMBIA National specific legislatio
Page 172 and 173: http://www.fdbghana.gov.gh/pdf/drug
Page 174 and 175: GUINEA BISSAU National specific leg
Page 176 and 177: (Accessed on 9 July 2008 at http://
Page 178 and 179: MALAWI National specific legislatio
Page 180 and 181: MAURITANIA National specific legisl
Page 184 and 185: MOZAMBIQUE National specific legisl
Page 186 and 187: 9) neBRA - Networking for Ethics on
Page 188 and 189: SAO TOME AND PRINCIPE National spec
Page 190 and 191: SEYCHELLES National specific legisl
Page 192 and 193: 10) Republic of South Africa, Depar
Page 194 and 195: SUDAN National specific legislation
Page 196 and 197: TANZANIA National specific legislat
Page 198 and 199: TOGO National specific legislation
Page 200 and 201: Conférence Annuelle, 2005 (Accesse
Page 202 and 203: 8) Republic of Uganda, National Hea
Page 204 and 205: ZIMBABWE National specific legislat
Page 206 and 207: ANNEXES INTERNATIONAL ROUND TABLE
Page 208 and 209: c) We recommend the appropriate ide
Page 210 and 211: AIFA INVITES 1) International and r
Page 212 and 213: 212
Page 214 and 215: Arab Republic of Egypt, Minister of
Page 216 and 217: Chong W., China sets up rules to co
Page 218 and 219: Collier J., Confusion over use of p
Page 220 and 221: Dramé B., Becker C., Samba Cor Sar
Page 222 and 223: Federal Democratic Republic of Ethi
Page 224 and 225: Hamza B., Spécificités et Rôle d
Page 226 and 227: Japan Pharmaceutical Manufacturers
Page 228 and 229: Repère Médical, La bioéthique da
Page 230 and 231: Molyneux C.S., Peshu N., Marsh K.,
Page 232 and 233:
Petrini C. (Ed.), Informed consent
Page 234 and 235:
Republic of South Africa, Medical R
Page 236 and 237:
République Tunisienne, Ministère
Page 238 and 239:
Struble K.A., Toigo T.A., Behrman R
Page 240 and 241:
UNESCO - United Nations Educational
Page 242 and 243:
Varmus H., Satcher D., Ethical Comp
Page 244 and 245:
WHO - World Health Organization, Na
Page 246 and 247:
246
Page 248:
REC R&D RMTC RBM SARETI SEAICRN TDR
show all

Biomedical Research in Developing Countries - UNICRI

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?